Checchi Capital Advisers LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 7.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,176 shares of the company’s stock after buying an additional 954 shares during the period. Checchi Capital Advisers LLC’s holdings in Novo Nordisk A/S were worth $565,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Trillium Asset Management LLC raised its stake in Novo Nordisk A/S by 0.4% in the second quarter. Trillium Asset Management LLC now owns 11,928 shares of the company’s stock valued at $512,000 after buying an additional 48 shares during the last quarter. Garrison Financial Corp raised its stake in Novo Nordisk A/S by 1.3% in the second quarter. Garrison Financial Corp now owns 11,675 shares of the company’s stock valued at $501,000 after buying an additional 145 shares during the last quarter. Mycio Wealth Partners LLC raised its stake in Novo Nordisk A/S by 0.8% in the first quarter. Mycio Wealth Partners LLC now owns 20,280 shares of the company’s stock valued at $695,000 after buying an additional 155 shares during the last quarter. Bessemer Group Inc. raised its stake in Novo Nordisk A/S by 0.7% in the second quarter. Bessemer Group Inc. now owns 33,388 shares of the company’s stock valued at $1,431,000 after buying an additional 247 shares during the last quarter. Finally, Global X Management Co. LLC raised its stake in Novo Nordisk A/S by 0.3% in the first quarter. Global X Management Co. LLC now owns 103,297 shares of the company’s stock valued at $3,541,000 after buying an additional 283 shares during the last quarter. Institutional investors and hedge funds own 6.33% of the company’s stock.

Shares of Novo Nordisk A/S (NVO) opened at 45.33 on Tuesday. The stock’s 50 day moving average is $42.78 and its 200-day moving average is $38.94. The stock has a market capitalization of $112.43 billion, a price-to-earnings ratio of 18.54 and a beta of 0.63. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $47.98.

The company also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be issued a dividend of $0.336 per share. This represents a yield of 1.07%. This is an increase from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend is Friday, August 18th. Novo Nordisk A/S’s dividend payout ratio is presently 36.00%.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/checchi-capital-advisers-llc-has-565000-position-in-novo-nordisk-as-nvo/1490173.html.

Several analysts have issued reports on the stock. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.